Daiichi Sankyo Company, Limited announced details of the application for its Take a New Challenge for Drug Discovery (TaNeDS) Europe 2017, a collaborative drug discovery initiative for universities and research institutes in Europe.
TaNeDS programme was launched in Japan in 2011 to help discover new lines of research through open innovation. From 2013, it has expanded outside of Japan, opening up to researchers in Germany, Switzerland and Austria and became known as TaNeDS Global Programme. Since 2014, it has expanded further across Europe to include all EU member states and was renamed “TaNeDS Europe” in 2015. The aim of this programme is increasing collaborative opportunities with researchers in Europe.
TaNeDS Europe 2017 Collaborative Drug Discovery Programme:. Eligible countries- All EU member states plus Iceland, Norway, Switzerland and Israel; Candidate research for application - New drug-target discovery, drug-target validation, and innovative technological research that could result in novel drug discovery and development.
Research themes: Cancer - New mechanisms and drug-target validation study for small-molecule and biologic treatments (antibody drugs, etc.); Pain and sensory neuron disorder - New mechanisms and drug treatments for pain and sensory neuronal systems in vision/hearing loss; End-organ diseases - New targets and mechanisms of end-organ diseases from heart, kidney, liver and vascular diseases; Other internal diseases - New mechanisms and drug treatments for rare diseases, gastrointestinal disorder and anaemia; Cell therapy - Research on novel somatic stem/progenitor cells, adoptive T-cell therapy and new technology on cell/gene modification; Revolutionary drug discovery technology - Novel technology on oncology, nucleic acid therapeutics, gene therapy and drug metabolism and pharmacokinetics.
For more details, please visit TaNeDS Europe webpage at: http://www.daiichisankyo.com/rd/taneds/index.html
Budget and period of research: Depending on the project type, up to maximum of 80,000 (Type A) or 150,000 (Type B) euros (plus overhead) per year for collaborative research projects for 2 years.
Eligibility: Researchers of any nationality employed by universities, research institutes and start-up companies within the EU as well as Iceland, Norway, Switzerland and Israel, who can conduct research in those countries.
Selection criteria: By matching Daiichi Sankyo’s research interests as well as demonstrating originality, potentiality and possibility of drug discovery.
Schedule: Application period - January 10 to February 20, 2017; First shortlist selection period - Late February to Mid-March, 2017; Second shortlist selection period - April, 2017; On-site visit interview - Mid-May, 2017; Notification of final decisions - Early June, 2017; Start of research programmes - August 2017 and onward.